These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10188965)

  • 41. Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
    Ohno Y; Okano M; Imaki J; Tatara A; Okumura T; Shimizu S
    Pharmacol Biochem Behav; 2010 Aug; 96(2):175-80. PubMed ID: 20460137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
    Sevak RJ; Koek W; France CP
    Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of 5HT2 receptor blockade on the startle reflex and its prepulse inhibition in mice and rats of various strains].
    Popova NK; Barykina NN; Alekhina TA; Naumenko KS; Kulikov AV
    Ross Fiziol Zh Im I M Sechenova; 1999 Jun; 85(6):857-64. PubMed ID: 10512006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.
    Kennett GA; Wood MD; Bright F; Cilia J; Piper DC; Gager T; Thomas D; Baxter GS; Forbes IT; Ham P; Blackburn TP
    Br J Pharmacol; 1996 Feb; 117(3):427-434. PubMed ID: 8821530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test.
    Ohno Y; Ishida K; Ikeda K; Ishibashi T; Okada K; Nakamura M
    Pharmacol Biochem Behav; 1994 Sep; 49(1):19-23. PubMed ID: 7816873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antagonism by the 5-HT2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat.
    Wadenberg ML; Ahlenius S
    Eur J Pharmacol; 1995 Dec; 294(1):247-51. PubMed ID: 8788438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro.
    Arvanov VL; Wang RY
    Neuropsychopharmacology; 1998 Mar; 18(3):197-209. PubMed ID: 9471117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors.
    Ohno Y; Imaki J; Mae Y; Takahashi T; Tatara A
    Neuropharmacology; 2011; 60(2-3):201-8. PubMed ID: 20813116
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72s (DRL-72s) schedule in rats: involvement of the serotonergic receptors in restoring the deficits.
    Jayarajan P; Nirogi R; Shinde A
    Eur J Pharmacol; 2013 Nov; 720(1-3):344-54. PubMed ID: 24135200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
    Beattie DT; Smith JA; Marquess D; Vickery RG; Armstrong SR; Pulido-Rios T; McCullough JL; Sandlund C; Richardson C; Mai N; Humphrey PP
    Br J Pharmacol; 2004 Nov; 143(5):549-60. PubMed ID: 15466450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy.
    Chartoff EH; Ward RP; Dorsa DM
    J Pharmacol Exp Ther; 1999 Nov; 291(2):531-7. PubMed ID: 10525068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.
    Bonhaus DW; Weinhardt KK; Taylor M; DeSouza A; McNeeley PM; Szczepanski K; Fontana DJ; Trinh J; Rocha CL; Dawson MW; Flippin LA; Eglen RM
    Neuropharmacology; 1997; 36(4-5):621-9. PubMed ID: 9225287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat.
    Kalkman HO; Neumann V; Nozulak J; Tricklebank MD
    Eur J Pharmacol; 1998 Feb; 343(2-3):201-7. PubMed ID: 9570468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats.
    Filip M; Bubar MJ; Cunningham KA
    Psychopharmacology (Berl); 2006 Jan; 183(4):482-9. PubMed ID: 16261316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety.
    Wood MD; Reavill C; Trail B; Wilson A; Stean T; Kennett GA; Lightowler S; Blackburn TP; Thomas D; Gager TL; Riley G; Holland V; Bromidge SM; Forbes IT; Middlemiss DN
    Neuropharmacology; 2001 Aug; 41(2):186-99. PubMed ID: 11489455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
    Moore NA; Blackman A; Awere S; Leander JD
    Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.
    Cussac D; Newman-Tancredi A; Nicolas JP; Boutin JA; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):549-54. PubMed ID: 10832610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
    Vanover KE; Harvey SC; Son T; Bradley SR; Kold H; Makhay M; Veinbergs I; Spalding TA; Weiner DM; Andersson CM; Tolf BR; Brann MR; Hacksell U; Davis RE
    J Pharmacol Exp Ther; 2004 Sep; 310(3):943-51. PubMed ID: 15102927
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice.
    Srinivas P; Subramanian AR; Brust P; Raghavan SA; Rangisetty JB; Gupta CN; Sridhar N; Veeranjaneyulu A; Parimoo P
    Farmaco; 1999 Aug; 54(8):567-72. PubMed ID: 10510854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.